Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961057 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL5683177 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL8333360 | 0.98 | CYP1A2 (0.46) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL11300211 | 0.92 | CXCR4 (0.44) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL9676237 | 0.87 | CXCR4 (0.49) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL27980795 | 0.86 | CXCR4 (0.51) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL18183309 | 0.85 | HTR1A (0.40) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL24322571 | 0.83 | ACHE (0.43) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL31058271 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A | |
| SCHEMBL24322374 | 0.83 | ACHE (0.43) | CYP1A2CYP2D6CHRM5ADRA2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | CYP1A2 160/4885CYP2D6 473/4885CHRM5 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.